Disrupted tau proteostasis and transneuronal spread is a pathological hallmark of Alzheimer's disease. Neurodegenerative diseases remain an unmet medical need and novel disease modifying therapeutics are paramount. Our objective was to develop a mechanistic mathematical model to enhance our understanding of tau antibody pharmacokinetics and pharmacodynamics in animals and humans. A physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) modeling approach was employed to support the preclinical development and clinical translation of therapeutic antibodies targeting tau for the treatment of Alzheimer's disease. The pharmacokinetics of a tau antibody was evaluated in rat and non-human primate microdialysis studies. Model validation for humans was performed using publicly available clinical data for gosuranemab. In-silico analyses were performed to predict tau engagement in human brain for a range of tau antibody affinities and various dosing regimens. PBPK-PD modeling enabled a quantitative understanding for the relationship between dose, affinity, and target engagement, which supported lead candidate optimization and predictions of clinically efficacious dosing regimens.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478891 | PMC |
| http://dx.doi.org/10.3389/fphar.2022.867457 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive Parent-Metabolite PBPK/PD Modeling Insights Into Methotrexate Personalized Dosing Strategies in Patients With Rheumatoid Arthritis.
CPT Pharmacometrics Syst Pharmacol
January 2025
Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rheumatoid arthritis (RA) is a major public health concern, which can cause serious outcomes. Low-dose methotrexate (MTX) is a cornerstone in RA treatment, but there is significant heterogeneity in clinical response. To evaluate underlying sources of pharmacokinetic variability and clinical response of MTX, a physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model was developed using PK-sim and Mobi (version 11.
View Article and Find Full Text PDFHaloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis.
J Psychopharmacol
January 2025
Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Background: Delirium is a severe neuropsychiatric disorder associated with increased morbidity and mortality. Numerous precipitating factors and etiologies merge into the pathophysiology of this condition which can be marked by agitation and psychosis. Judicious use of antipsychotic medications such as intravenous haloperidol reduces these symptoms and distress in critically ill individuals.
View Article and Find Full Text PDFWhat matters for drug delivery to tumor by nanoparticles: Gaining insights from PBPK/PD simulation of drug nanocrystals.
ADMET DMPK
July 2024
Department of Industrial & Physical Pharmacy, Purdue University, West Lafayette, Indiana, United States.
Background And Purpose: In our previous studies, drug nanocrystals were directly prepared by solution crystallization, possessing uniform particle size and morphology suitable for intravenous (IV) injection. These nanocrystals accumulated in a small percentage of their injected dose in tumor-bearing mice but showed similar anti-tumor effectiveness and much-reduced side effects compared with current commercial solubilized and encapsulated delivery systems.
Experimental Approach: In this study, we aimed to delineate possible controlling factors for the pharmacokinetics (PK) and biodistribution behaviors of paclitaxel (PTX) nanocrystals tested in mice by applying physiologically based pharmacokinetics (PBPK) modeling, coupled with pharmacodynamics (PD) simulation, to the data.
Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients.
Sci Rep
August 2024
Department of Pharmacy, The Third People's Hospital of Chengdu, College of Medicine, Southwest Jiaotong University, Chengdu, China.
This study aimed to develop a physiologically based pharmacokinetic/pharmacodynamic model (PBPK/PD) of meropenem for critically ill patients. A PBPK model of meropenem in healthy adults was established using PK-Sim software and subsequently extrapolated to critically ill patients based on anatomic and physiological parameters. The mean fold error (MFE) and geometric mean fold error (GMFE) methods were used to compare the differences between predicted and observed values of pharmacokinetic parameters C, AUC, and CL to evaluate the accuracy of the PBPK model.
View Article and Find Full Text PDFProgress in physiologically based pharmacokinetic-pharmacodynamic models of amino acids in humans.
Curr Opin Clin Nutr Metab Care
November 2024
Department of Biomedical Physiology and Kinesiology.
Article Synopsis
- - The review discusses the importance of amino acids for health, their roles in proteins, metabolism, and signaling, and highlights the use of physiologically based pharmacokinetic and pharmacodynamic (PBPK-PD) modeling to better understand amino acid functions.
- - Recent PBPK-PD models have provided insights into amino acid metabolism, including how leucine affects muscle protein metabolism and optimal supplementation strategies for conditions like sickle-cell disease and seizure disorders.
- - These models offer potential for future research in various areas, such as treatments for sarcopenia, comparisons between animal and plant-based nutrition, and understanding nutrient-drug interactions in diseases like Parkinson’s.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!